Brolucizumab versus aflibercept in treating exudative age-related macular degeneration: a 12-month pro re nata regimen.

Sci Rep · 2026 · PMC12873363 · PMID 41491306

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

The number of additional injections showed a trend favoring IVBr over IVA but the difference was insignificant ( P = 0.055).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.